AIM: To analyze the risk factors of hepatocellular carcinoma (HCC) recurrence after radiofrequency ablation (RFA) treatment with HCV-associated hepatitis. METHODS: Twenty-six patients with HCV-associated HCC who were followed-up for more than 12 mo were selected for this study. Risk factors for distant intrahepatic recurrences of HCC were evaluated for patients in whom complete coagulation was achieved without recurrence in the same subsegment as the primary nodule. Twelve clinical and tumoral factors were examined: Age, gender, nodule diameter, number of primary HCC nodule, Child-Pugh classification, serum platelet, serum albumin, serum AST, post RFA AST, serum ALT, post RFA ALT, post RFA treatment. RESULTS: Distant recurrences of HCC in remnant liver after RFA were observed in 14 cases and in the number of primary HCC nodules (P = 0.047), and the serum platelets (P = 0.030), the clear difference came out by the recurrence group and the non-recurrence group. The cumulative recurrence rates after 1 and 2 years were 30.8% and 86.8%, respectively for primary multinodular HCC, and 15.4% and 29.5% respectively, for primary uninodular HCC. In addition the 1-year recurrence rates for patients with serum albumin more than 3.4 g/dL and less than 3.4 g/dL were 23.1% for both, but the 2-years recurrence rates were 89.0% and 23.1%, respectively. The number of primary HCC nodules (relative risk, 6.970; P = 0.016) were found to be a statistically significant predictor for poor distant intrahepatic recurrence by univariate analysis. CONCLUSION: Patients who have multiple HCC nodules, low serum platelets and low serum albumin accompanied by HCV infection, should be carefully followed because of the high incidence of new HCC lesions in the remnant liver, even if coagulation RFA is complete.
AIM: To analyze the risk factors of hepatocellular carcinoma (HCC) recurrence after radiofrequency ablation (RFA) treatment with HCV-associated hepatitis. METHODS: Twenty-six patients with HCV-associated HCC who were followed-up for more than 12 mo were selected for this study. Risk factors for distant intrahepatic recurrences of HCC were evaluated for patients in whom complete coagulation was achieved without recurrence in the same subsegment as the primary nodule. Twelve clinical and tumoral factors were examined: Age, gender, nodule diameter, number of primary HCC nodule, Child-Pugh classification, serum platelet, serum albumin, serum AST, post RFA AST, serum ALT, post RFA ALT, post RFA treatment. RESULTS: Distant recurrences of HCC in remnant liver after RFA were observed in 14 cases and in the number of primary HCC nodules (P = 0.047), and the serum platelets (P = 0.030), the clear difference came out by the recurrence group and the non-recurrence group. The cumulative recurrence rates after 1 and 2 years were 30.8% and 86.8%, respectively for primary multinodular HCC, and 15.4% and 29.5% respectively, for primary uninodular HCC. In addition the 1-year recurrence rates for patients with serum albumin more than 3.4 g/dL and less than 3.4 g/dL were 23.1% for both, but the 2-years recurrence rates were 89.0% and 23.1%, respectively. The number of primary HCC nodules (relative risk, 6.970; P = 0.016) were found to be a statistically significant predictor for poor distant intrahepatic recurrence by univariate analysis. CONCLUSION:Patients who have multiple HCC nodules, low serum platelets and low serum albumin accompanied by HCV infection, should be carefully followed because of the high incidence of new HCC lesions in the remnant liver, even if coagulation RFA is complete.
Authors: Y Koike; Y Shiratori; S Sato; S Obi; T Teratani; M Imamura; K Hamamura; Y Imai; H Yoshida; S Shiina; M Omata Journal: Hepatology Date: 2000-12 Impact factor: 17.425
Authors: Robert J Fontana; Halimi Hamidullah; Hanh Nghiem; Joel K Greenson; Hero Hussain; Jorge Marrero; Steve Rudich; Leslie A McClure; Juan Arenas Journal: Liver Transpl Date: 2002-12 Impact factor: 5.799
Authors: K Ikeda; S Saitoh; Y Arase; K Chayama; Y Suzuki; M Kobayashi; A Tsubota; I Nakamura; N Murashima; H Kumada; M Kawanishi Journal: Hepatology Date: 1999-04 Impact factor: 17.425
Authors: M Pompili; G L Rapaccini; F de Luca; E Caturelli; A Astone; D A Siena; M R Villani; A Grattagliano; A Cedrone; G Gasbarrini Journal: Cancer Date: 1997-04-15 Impact factor: 6.860
Authors: Jeong Han Kim; Hyung Joon Yim; Kwang Gyun Lee; Seung Young Kim; Eun Suk Jung; Young Kul Jung; Ji Hoon Kim; Yeon Seok Seo; Jong Eun Yeon; Hong Sik Lee; Soon Ho Um; Kwan Soo Byun; Ho Sang Ryu Journal: Hepatol Int Date: 2011-07-05 Impact factor: 6.047
Authors: D G Ward; Y Cheng; G N'Kontchou; T T Thar; N Barget; W Wei; A Martin; M Beaugrand; P J Johnson Journal: Br J Cancer Date: 2006-10-24 Impact factor: 7.640
Authors: Sang Hoon Lee; Seung Up Kim; Jeong Won Jang; Si Hyun Bae; Sanghun Lee; Beom Kyung Kim; Jun Yong Park; Do Young Kim; Sang Hoon Ahn; Kwang-Hyub Han Journal: Onco Targets Ther Date: 2015-02-02 Impact factor: 4.147